Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitors, according to a two-year, follow-up analysis of the ICARIA-MM study However the CD38-directed monoclonal antibody may find it difficult to make its mark in the Australian setting any time soon. The study, published...Continue Reading